Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Kreuter, Michael ^a,b   Bonella, Francesco ^c   Wijsenbeek, Marlies ^d   Maher, Toby M ^e,f   Spagnolo, Paolo ^g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c RUHRLANDKLINIK   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTACID AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; IMATINIB; MACITENTAN; NINTEDANIB; PIRFENIDONE; RESPIRATORY TRACT AGENT; SILDENAFIL; WARFARIN; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

DISEASE COURSE; DRUG EFFICACY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG TRANSPLANTATION; META ANALYSIS; MONOTHERAPY; PALLIATIVE THERAPY; PATIENT REFERRAL; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AGED; COMORBIDITY; DISEASE MANAGEMENT; IDIOPATHIC PULMONARY FIBROSIS; PATHOLOGY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMORBIDITY; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES;

EID: 84953264465     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/329481     Document Type: Review

References (71)

1. G. Raghu, H. R. Collard, J. J. Egan et al., "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, " American Journal of Respiratory and Critical CareMedicine, vol. 183, no. 6, pp. 788-824, 2011.
2. P. Spagnolo, N. Sverzellati, G. Rossi et al., "Idiopathic pulmonary fibrosis: an update, " Annals of Medicine, vol. 47, no. 1, pp. 15-27, 2015.
3. G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster, "Incidence and prevalence of idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 810-816, 2006.
4. G. Raghu, S.-Y. Chen, W.-S. Yeh et al., "Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11, " The Lancet Respiratory Medicine, vol. 2, no. 7, pp. 566-572, 2014.
5. J. Hutchinson, A. Fogarty, R. Hubbard, and T. McKeever, "Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review, " The European Respiratory Journal, vol. 46, no. 3, pp. 795-806, 2015.
6. GBD 2013 Mortality and Causes of Death Collaborators, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, " The Lancet, vol. 385, pp. 117-171, 2015.
7. K. Iwai, T. Mori, N. Yamada, M. Yamaguchi, and Y. Hosoda, "Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure, " American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 3, pp. 670-675, 1994.
8. A. L. Olson and J. J. Swigris, "Idiopathic pulmonary fibrosis: diagnosis and epidemiology, " Clinics in Chest Medicine, vol. 33, no. 1, pp. 41-50, 2012.
9. P. Spagnolo, J. Grunewald, and R. M. du Bois, "Genetic determinants of pulmonary fibrosis: evolving concepts, " The Lancet Respiratory Medicine, vol. 2, no. 5, pp. 416-428, 2014.
10. J. A. Bjoraker, J. H. Ryu, M. K. Edwin et al., "Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 1, pp. 199-203, 1998.
11. K. R. Flaherty, G. B. Toews, W. D. Travis et al., "Clinical significance of histological classification of idiopathic interstitial pneumonia, " European Respiratory Journal, vol. 19, no. 2, pp. 275-283, 2002.
12. J. Behr, M. M. Hoeper, M. Kreuter, J. Klotsche, H. Wirtz, and D. Pittrow, "Characteristics and management of idiopathic pulmonary fibrosis: the INSIGHTS-IPF registry, " Deutsche Medizinische Wochenschrift, vol. 137, no. 49, pp. 2586-2588, 2012.
13. T. E. King Jr., M. I. Schwarz, K. Brown et al., "Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality, " American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 6, pp. 1025-1032, 2001.
14. B. Ley, H. R. Collard, and T. E. King Jr., "Clinical course and prediction of survival in idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical CareMedicine, vol. 183, no. 4, pp. 431-440, 2011.
15. American Thoracic Society (ATS) and European Respiratory Society (ERS), "Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement, " American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, pp. 646-664, 2000.
16. M. Selman and A. Pardo, "Revealing the pathogenic and agingrelated mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model, " American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 10, pp. 1161-1172, 2014.
17. P. Spagnolo, G. Rossi, and A. Cavazza, "Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications, " Expert Reviewof Clinical Immunology, vol. 10, no. 8, pp. 1005-1017, 2014.
18. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, "The New England Journal of Medicine, vol. 370, no. 22, pp. 2083-2092, 2014.
19. L. Richeldi, R. M. DuBois, G. Raghuet al., "Efficacyand safetyof nintedanib in idiopathic pulmonary fibrosis, " The New England Journal of Medicine, vol. 370, no. 22, pp. 2071-2082, 2014.
20. M. Kreuter, "Pirfenidone: an update on clinical trial data and insights from everyday practice, " European Respiratory Review, vol. 23, no. 131, pp. 111-117, 2014.
21. Idiopathic Pulmonary Fibrosis Clinical Research Network, F. J. Martinez, J. A. de Andrade, K. J. Anstrom, T. E. King Jr., and G. Raghu, "Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis, "The New England Journal of Medicine, vol. 366, pp. 1968-1977, 2012.
22. I. Noth, K. J. Anstrom, S. B. Calvert et al., "Aplacebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical CareMedicine, vol. 186, no. 1, pp. 88-95, 2012.
23. G. Raghu, B. Rochwerg, Y. Zhang et al., "An official ATS/ERS/ JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline, " American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 2, pp. e3-e19, 2015.
24. S. N. Iyer, G. Gurujeyalakshmi, and S. N. Giri, "Effects of pirfenidone on transforming growth factor- gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis, " Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 1, pp. 367-373, 1999.
25. H. Oku, T. Shimizu, T. Kawabata et al., "Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis, " European Journal of Pharmacology, vol. 590, no. 1-3, pp. 400-408, 2008.
26. H. Taniguchi, M. Ebina, Y. Kondoh et al., "Pirfenidone in idiopathic pulmonary fibrosis, " The European Respiratory Journal, vol. 35, no. 4, pp. 821-829, 2010.
27. P. W. Noble, C. Albera, W. Z. Bradford et al., "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, " The Lancet, vol. 377, no. 9779, pp. 1760-1769, 2011.
28. P. Spagnolo, C. Del Giovane, F. Luppi et al., "Non-steroid agents for idiopathic pulmonary fibrosis, " Cochrane Database of Systematic Reviews, no. 9, Article IDCD003134, 2010.
29. U. Costabel, E. Bendstrup, V. Cottin et al., "Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events, " Advances in Therapy, vol. 31, pp. 375-391, 2014, Erratum in Advances in Therapy, vol. 31, no. 5, pp. 575-576, 2014.
30. G. M. Keating, "Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis, " Drugs, vol. 75, no. 10, pp. 1131-1140, 2015.
31. N. Ahluwalia, B. S. Shea, and A. M. Tager, "New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses, " American Journal of Respiratory and Critical CareMedicine, vol. 190, no. 8, pp. 867-878, 2014.
32. L. Richeldi, V. Cottin, K. R. Flaherty et al., "Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis, " Respiratory Medicine, vol. 108, no. 7, pp. 1023-1030, 2014.
33. G. Raghu, T. D. Freudenberger, S. Yang et al., "High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis, " European Respiratory Journal, vol. 27, no. 1, pp. 136-142, 2006.
34. J. S. Lee, J. H. Ryu, B. M. Elicker et al., "Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 12, pp. 1390-1394, 2011.
35. J. S. Lee, H. R. Collard, K. J. Anstromet al., "Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials, " The Lancet Respiratory Medicine, vol. 1, no. 5, pp. 369-376, 2013.
36. N. Galìe, M. Humbert, J. L. Vachiery et al., "ESC/ERSGuidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), " European Respiratory Journal, vol. 46, no. 5, pp. 903-975, 2015.
37. H. R. Collard, K. J. Anstrom, M. I. Schwarz, and D. A. Zisman, "Sildenafil improves walk distance in idiopathic pulmonary fibrosis, " Chest, vol. 131, no. 3, pp. 897-899, 2007.
38. Idiopathic Pulmonary Fibrosis Clinical Research Network, D. A. Zisman, M. Schwarz et al., "A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis, " The New England Journal of Medicine, vol. 363, no. 7, pp. 620-628, 2010.
39. M. K. Han, D. S. Bach, P. G. Hagan et al., "Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction, " Chest, vol. 143, no. 6, pp. 1699-1708, 2013.
40. T. E. King Jr., J. Behr, K. K. Brownet al., "BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 75-81, 2008.
41. T. E. King Jr., K. K. Brown, G. Raghu et al., "BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 1, pp. 92-99, 2011.
42. G. Raghu, R. Million-Rousseau, A. Morganti, L. Perchenet, J. Behr, and MUSIC Study Group, "Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial, " European Respiratory Journal, vol. 42, no. 6, pp. 1622-1632, 2013.
43. A. M. Cantin, R. C. Hubbard, and R. G. Crystal, "Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis, " American Review of Respiratory Disease, vol. 139, no. 2, pp. 370-372, 1989.
44. H. Tomioka, Y. Kuwata, K. Imanaka et al., "A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis, " Respirology, vol. 10, no. 4, pp. 449-455, 2005.
45. S. Homma, A. Azuma, H. Taniguchi et al., "Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis, " Respirology, vol. 17, no. 3, pp. 467-477, 2012.
46. Idiopathic Pulmonary Fibrosis Clinical Research Network, F. J. Martinez, J. A. de Andrade, K. J. Anstrom, T. E. King Jr., and G. Raghu, "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, "The New England Journal of Medicine, vol. 370, no. 22, pp. 2093-2101, 2014.
47. J. M. Oldham, S.-F. Ma, F. J. Martinez et al., "TOLLIP, MUC5B and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, 2015.
48. C. S. King and S. D. Nathan, "Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis, " Current Opinion in Pulmonary Medicine, vol. 21, pp. 479-489, 2015.
49. P. Spagnolo, R. M. duBois, and V. Cottin, "Rare lungdisease and orphan drug development, " The Lancet Respiratory Medicine, vol. 1, no. 6, pp. 479-487, 2013.
50. P. Spagnolo, A. U. Wells, and H. R. Collard, "Pharmacological treatment of idiopathic pulmonary fibrosis: an update, " Drug Discovery Today, vol. 20, pp. 514-524, 2015.
51. J. M. Harris, I. D. A. Johnston, R. Rudd, A. J. Newman Taylor, and P. Cullinan, "Cryptogenic fibrosing alveolitis and lung cancer: the BTS study, " Thorax, vol. 65, no. 1, pp. 70-76, 2010.
52. Y. Ozawa, T. Suda, T. Naito et al., "Cumulative incidence of and predictive factors for lung cancer in IPF, " Respirology, vol. 14, no. 5, pp. 723-728, 2009.
53. C. E. Daniels and J. R. Jett, "Does interstitial lung disease predispose to lung cancer?" Current Opinion in Pulmonary Medicine, vol. 11, no. 5, pp. 431-437, 2005.
54. M.-C. Aubry, J. L. Myers, W. W. Douglas et al., "Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis, " Mayo Clinic Proceedings, vol. 77, no. 8, pp. 763-770, 2002.
55. R. J. Panos, R. L. Mortenson, S. A. Niccoli, and T. E. King Jr., "Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment, " The American Journal of Medicine, vol. 88, no. 4, pp. 396-404, 1990.
56. M. Kreuter, S. Ehlers-Tenenbaum, M. Schaaf et al., "Treatment and outcome of lung cancer in idiopathic interstitial pneumonias, " Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 31, no. 4, pp. 266-274, 2015.
57. S. Tomassetti, C. Gurioli, J. H. Ryu et al., "The impact of lung cancer on survival of idiopathic pulmonary fibrosis, " Chest, vol. 147, no. 1, pp. 157-164, 2015.
58. C. D. Fell, "Idiopathic pulmonary fibrosis: phenotypes and comorbidities, " Clinics in ChestMedicine, vol. 33, no. 1, pp. 51-57, 2012.
59. K. C. Meyer, S. K. Danoff, L. H. Lancaster, and S. D. Nathan, "Management of idiopathic pulmonary fibrosis in the elderly patient, " CHEST Journal, vol. 148, no. 1, pp. 242-452, 2015.
60. R. M. du Bois, D. Weycker, C. Albera et al., "Six-minutewalk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference, " American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 9, pp. 1231-1237, 2011.
61. R. M. du Bois, C. Albera, W. Z. Bradford et al., "6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis, " European Respiratory Journal, vol. 43, no. 5, pp. 1421-1429, 2014.
62. P. W. Noble, C. Albera, W. Z. Bradford et al., "Analysis of pooled data from 3 phase 3, multinational, randomized, double-blind, placebo controlled trials evaluating pirfenidone in patients with idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 189, Article ID A1423, 2014.
63. W. A. Wuyts, K. M. Antoniou, K. Borensztajn et al., "Combination therapy: the future of management for idiopathic pulmonary fibrosis?" The Lancet Respiratory Medicine, vol. 2, no. 11, pp. 933-942, 2014.
64. T. Ogura, H. Taniguchi, A. Azuma et al., "Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis, " European Respiratory Journal, vol. 45, no. 5, pp. 1382-1392, 2015.
65. T. M. Maher, "Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine, " Current Opinion in Pulmonary Medicine, vol. 19, no. 5, pp. 460-465, 2013.
66. P. Spagnolo, A. Tzouvelekis, and T. M. Maher, "Personalized medicine in idiopathic pulmonary fibrosis: facts and promises, " Current Opinion in PulmonaryMedicine, vol. 21, no. 5, pp. 470-478, 2015.
67. C. D. Fell, F. J. Martinez, L. X. Liu et al., "Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical CareMedicine, vol. 181, no. 8, pp. 832-837, 2010.
68. F. Novelli, L. Tavanti, S. Cini et al., "Determinants of the prognosis of idiopathic pulmonary fibrosis, " European Review forMedical and Pharmacological Sciences, vol. 18, no. 6, pp. 880-886, 2014.
69. H. Sumikawa, T. Johkoh, K. Fujimoto et al., "Pathologically proved nonspecific interstitial pneumonia: CT pattern analysis as compared with usual interstitial pneumonia CT Pattern, " Radiology, vol. 272, no. 2, pp. 549-556, 2014.
70. A. S. Chang, J. Munson, A. H. Gifford, and D. A. Mahler, "Prospective use of descriptors of dyspnea to diagnose common respiratory diseases, " CHEST Journal, vol. 148, no. 4, pp. 895-902, 2015.
71. G. Raghu, D. Lynch, J. D. Godwin et al., "Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial, " The Lancet Respiratory Medicine, vol. 2, no. 4, pp. 277-284, 2014.